Sevion Therapeutics
Pioneering groundbreaking therapies for cancer and immunological diseases with innovative antibody technology platforms.
Pioneering groundbreaking therapies for cancer and immunological diseases with innovative antibody technology platforms.
Sevion Therapeutics is a biopharmaceutical company that specializes in discovering, developing, and acquiring innovative therapies for cancer and immunological diseases. The company's unique antibody technology platforms enable the development of proprietary and partnered therapies that target difficult-to-reach areas such as multispanning membrane proteins and ion channels, playing crucial roles in various diseases. Founded in 1964, Sevion has also pioneered the creation of the first protein nanocage system designed to deliver nucleic acids and other therapeutic substances directly to target cells.
With a focus on Biopharma, Biotechnology, Health and Wellness, and Pharmaceutical industries, Sevion has secured a $3.02M Post-IPO Equity investment on 19 May 2015.
Sevion's innovative approach and dedication to addressing challenging medical conditions through pioneering therapies position it as a promising venture for potential investors in the biopharmaceutical sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $3.02M | - | 19 May 2015 | |
| Post-IPO Equity | $1.73M | - | 01 Oct 2013 | |
| Post-IPO Equity | $11.50M | 10 |
|
29 Mar 2010 |
No recent news or press coverage available for Sevion Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
